(Total Views: 597)
Posted On: 03/02/2021 1:54:31 PM
Post# of 153907
Thank you Tech. Excellent post. A few questions for you:
1) If GM-CSF is low, does that indicate that therapeutics that suppress GM-CSF could exacerbate Longhaulers?
2) If Dr. Patterson is correct that a CCR5 antagonist will normalize these markers, how do we compare to others such as Maraviroc? I know it has a black box warning, but I assume it could be used in short term safely.
3) How many doses do we think Longhaulers will need? I know Dr. Patterson is advocating precision medicine, but I am curious if this is something that could be a one or two shot therapy.
4) Does anyone know how we compare to Maraviroc with respect to cost, ability to manufacture, etc?
I am hopeful that we are able to contribute in the longhauler arena, but given the size I worry that a cheaper alternative may be preferable.
1) If GM-CSF is low, does that indicate that therapeutics that suppress GM-CSF could exacerbate Longhaulers?
2) If Dr. Patterson is correct that a CCR5 antagonist will normalize these markers, how do we compare to others such as Maraviroc? I know it has a black box warning, but I assume it could be used in short term safely.
3) How many doses do we think Longhaulers will need? I know Dr. Patterson is advocating precision medicine, but I am curious if this is something that could be a one or two shot therapy.
4) Does anyone know how we compare to Maraviroc with respect to cost, ability to manufacture, etc?
I am hopeful that we are able to contribute in the longhauler arena, but given the size I worry that a cheaper alternative may be preferable.
(0)
(0)
